

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

28 FEB 2005

PCT 03 / 0 1 3 5 2

10/25783

REC'D 16 SEP 2003

WFO

PCT

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0202598-9
Patent application number

(86) Ingivningsdatum 2002-09-02
Date of filing

Stockholm, 2003-09-03

För Patent- och registreringsverket
For the Patent- and Registration Office


Sonia André

Avgift
Fee

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

PATENT- OCH
REGISTRERINGSVERKET
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

BEST AVAILABLE COPY

Alpha-7 Nicotinic Receptor Agonists and Statins In Combination

Field of Invention:

This invention is concerned with the treatment of neurological degenerative diseases and particularly with the treatment of Alzheimer's disease.

Background

The etiology of Alzheimer's disease is complex and not entirely understood. Current hypotheses point to the overproduction of the amyloid peptide A β as a causative factor in the cognitive deficits and neurodegeneration associated with Alzheimer's disease (Selkoe, 2001; Walsh *et. al.*, 2002). In addition, epidemiological studies have shown that hypercholesterolemia is a risk factor for Alzheimer's disease (Jarvik *et. al.*, 1995; Notkola *et. al.*, 1998). Further, it has recently been shown that the administration of statins is associated with a decreased risk of Alzheimer's disease (Jick *et. al.*, 2000; Woloizin *et. al.*, 2000). Still further, another recent study has shown that the statin lovastatin reduced A β plasma levels in human subjects that had elevated plasma levels of low-density lipoprotein cholesterol (Buxbaum *et. al.*, 2002).

Alpha-7 nicotinic receptors (α 7-nAChR) are ligand-gated ion channels that allow for the entry into cells of calcium and other monovalent cations (Dani, 2001). α 7-nAChR have been shown to play an important role in regulating neurotransmitter release, hippocampal synaptic function, neuroprotection against a variety of insults, and cognition (Dani, 2001; Dahas-Bailador *et. al.*, 2000; Rezvani and Levin, 2001).

Recent studies imply an interaction between A β and α 7-nAChR that may contribute to the pathophysiology of Alzheimer's disease. A β has been shown to potently inhibit α 7-nAChR (Liu *et. al.*, 2001). It has been proposed that this inhibitory effect of A β on α 7-nAChR function may contribute to cognitive deficits in Alzheimer's disease. Neurodegeneration induced by the activation of NMDA glutamatergic receptors is also enhanced in the presence of A β (Kihara *et. al.*, 2001). This A β induced neurodegeneration is inhibited by activation of α 7-nAChR.

Background References:

Buxbaum JD, Cullen EI and Friedhoff LT: Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. *Frontiers in Bioscience* 7:a50-a59, 2002.

Dajas-Bailador FA, Lima PA and Wonnacott S: The $\alpha 7$ nicotinic receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca^{2+} dependent mechanism. *Neuropharmacology* 39:2799-2807, 2000.

5 Dani JA: Overview of nicotinic receptors and their roles in the central nervous system. *Biol Psychiatry* 49:166-174, 2001.

Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Toshiaki K, and Akaike A: $\alpha 7$ Nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block $\text{A}\beta$ -amyloid-induced neurotoxicity. *J Biol Chem* 276:13541-13546, 1998.

10 Jick H, Zornberg GL, Jick SS, Seshadri S, and Drachman DA: Statins and the risk of dementia. *Lancet* 356:1627-1631, 2000.

Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C and Larson EB: Interactions of apolipoprotein E genotype, total cholesterol, age, and sex in prediction of Alzheimer's disease. *Neurology* 45:1092-1096, 1995.

15 Liu Q, Kawai H and Berg DK: b-Amyloid peptide blocks the response of $\alpha 7$ -containing nicotinic receptors on hippocampal neurons. *Proc Natl Acad Sci* 97:10197-10202, 2001.

Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J and Nissinen A: Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. *Neuroepidemiology* 17:14-20, 1998.

20 Rezvani AH and Levin ED: Cognitive effects of nicotine. *Biol Psychiatry* 49:258-267, 2001.

Selkoe, DJ: Alzheimer's disease: Genes, proteins, and therapy. *Physiological Reviews* 81:741-766, 2001.

25 Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, and Selkoe, DJ: Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416:535-539, 2002.

Wolozin B, Kellman W, Ruosseau P, Celesia GG, and Siegel G: Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arch Neurol* 57:1439-1443, 2000.

30 **Description of the Invention:**

We have discovered that statins and $\alpha 7$ -nAChR agonists in combination have the potential to alter the pathophysiology of Alzheimer's disease and symptoms. The different mechanisms by which statins and $\alpha 7$ -nAChR agonists operate — statins by reducing the

formation of the neurotoxic substance A β and α 7-nAChR agonists by blocking the cognitive impairing and neurotoxic effects of A β — imply that a statin and an α 7-nAChR in combination will synergistically benefit patients suffering with neurological degenerative diseases and particularly patients suffering with Alzheimer's disease.

5 In one aspect the invention is a method for treating neurological degenerative diseases and particularly Alzheimer's disease comprising treatment with a combination comprising an α 7-nAChR agonist and a statin.

A combination suitable for practicing the invention comprises a statin selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin sodium, simvastatin or
10 rosuvastatin, or a pharmaceutically-acceptable salt thereof and an α 7-nAChR agonist selected from spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one,

(+)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one,

(-)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one,

spiro[1-azabicyclo[2.2.1]heptan-3,5'-oxazolidin-2'-one],

15 3'-methyl spiro-[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one],

spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-phenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-nitrospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

20 1'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline],

5'-(phenylcarboxamido)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-

b]pyridine],

5'-(phenylaminocarbonylamino)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-

b]pyridine],

25 5'-(phenylsulfonylamido)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-

b]pyridine],

5'-aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-N-methylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-N,N-dimethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-

30 b]pyridine],

5'-N,N-diethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-N-ethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

5'-N-benzylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

- 5'-N-formamidospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-N-acetamidospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline],
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]quinoline],
5'-ethenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-(E)-(phenylethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
b]pyridine],
5'-(4-morpholino)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-(1-azetidiny)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-(E)-(2-(4-pyridyl)ethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
b]pyridine],
5'-(E)-(2-(2-pyridyl)ethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
b]pyridine],
5'-(2-trimethylsilylethynyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
b]pyridine],
5'-ethynylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-(2-furyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-(3-pyridyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-methylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5' carbonitrile],
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5' carboxamide],
5'-N'-(3-chlorophenyl)aminocarbonylminospiro[1-azabicyclo[2.2.2]octane-3,2'-(
3'H)-furo[2,3-b]pyridine],
5'-N'-(2-nitrophenyl)aminocarbonylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(
3'H)-furo[2,3-b]pyridine],
4'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
4'-methoxyspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
4'-phenylthiospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
4'-(N-2-aminoethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
b]pyridine],
4'-phenylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
4'-methylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-(4-N-methylpiperazin-1-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

4'-chloro-spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[3,2-c]pyridine],

spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[3,2-c]pyridine],

5 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-7'-oxide],

spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-6'-carbonitrile],

6'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

6'-fluorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylfuran-2-carboxamide),

10 N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-thienyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-phenylbenzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-pyridyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),

15 N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methoxyphenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-methoxyphenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-(N-acetylamino)phenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-fluorophenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methylphenyl)benzamide),

20 N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-thienyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3,5-dichlorophenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-naphthyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(4-fluorophenyl)benzamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)furan-2-carboxamide),

25 N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-thienyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-benzo[b]furanyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-thienyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)furan-2-carboxamide),

30 N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-methoxyphenyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-fluorophenyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-naphthyl)furan-2-carboxamide),

N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methylphenyl)furan-2-carboxamide),

PRU-09-02

- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-furyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-furyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
5 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(2-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(4-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(3-pyridyl)thiophene-2-carboxamide),
10 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-nitrophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-trifluoromethylphenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)thiophene-2-
15 carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-ethoxyphenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)furan-2-carboxamide),
20 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)thiophene-2-
carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-chlorophenyl)furan-2-carboxamide),
25 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiazole-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiazole-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)thiophene-2-
carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(8-quinoliny)thiophene-2-carboxamide),
30 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-phenylthiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-cyanophenyl)thiophene-2-carboxamide),

- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-methylamino)phenyl)thiophene-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-hydroxyphenyl)thiophene-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridylamino)thiophene-2-carboxamide),
- 5 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)thiophene-2-carboxamide),
- N*-(1-aza-bicyclo[2.2.2]oct-3-yl)(5-(3-(4-morpholinyl)phenyl)thiophene-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(aminomethyl)phenyl)thiophene-2-carboxamide),
- 10 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenoxythiophene-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)furan-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)furan-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-formylphenyl)thiophene-2-carboxamide); *N*-
- 15 (1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(hydroxymethyl)phenyl)thiophene-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylfuran-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-thienyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-phenylbenzamide),
- 20 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-pyridyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methoxyphenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-methoxyphenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-(*N*-acetylamino)phenyl)benzamide);
- 25 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-fluorophenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methylphenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-thienyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3,5-dichlorophenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-naphthyl)benzamide),
- 30 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(4-fluorophenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-thienyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-benzo[b]furanyl)furan-2-carboxamide),

- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-thienyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-methoxyphenyl)furan-2-carboxamide),
5 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-fluorophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-naphthyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methylphenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-furyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-furyl)furan-2-carboxamide),
10 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(2-pyridyl)thiophene-2-carboxamide),
15 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(4-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(3-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)furan-2-
carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-nitrophenyl)furan-2-carboxamide),
20 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-trifluoromethylphenyl)furan-2-
carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)thiophene-2-
carboxamide),
25 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-ethoxyphenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)furan-2-
carboxamide),
30 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)thiophene-2-
carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-3-carboxamide),

(R) - N -(1-azabicyclo[2.2.2]oct-3-yl)[5-(4-chlorophenyl)furan-2-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiazole-3-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiazole-3-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(N,N -dimethylamino)phenyl)thiophene-2-
5 carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(8-quinoliny)thiophene-2-carboxamide),
 (S) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide);
 (S) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
 (S) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),
10 (S) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-3-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(4-phenylthiophene-2-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-cyanophenyl)thiophene-2-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(N -methylamino)phenyl)thiophene-2-
15 carboxamide),
 (R) - N -(1-aza-bicyclo[2.2.2]oct-3-yl)(5-(3-hydroxyphenyl)thiophene-2-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridylamino)thiophene-2-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)thiophene-2-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(4-morpholinyl)phenyl)thiophene-2-
20 carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(aminomethyl)phenyl)thiophene-2-
carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-phenoxythiophene-2-carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)furan-2-carboxamide) ,
25 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(N,N -dimethylamino)phenyl)furan-2-
carboxamide),
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-formylphenyl)thiophene-2-carboxamide), or
 (R) - N -(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(hydroxymethyl)phenyl)thiophene-2-
carboxamide), or a pharmaceutically-acceptable salt thereof.

30 In general, it is contemplated that any statin when used in combination with any
alpha-7-nAChR agonist will be useful in practicing the present invention.

Alpha-7-nAChR agonists contemplated to be useful in the present invention are
described in international publications WO9606098, WO9730998, WO 9903859,

WO9956745, WO0042044, WO0129034, WO0160821, WO0132622, WO0136417, WO0132619, WO0132620, WO0136417, WO0244176, WO0220521, WO0216358, WO0216357, WO0216356, WO0216355, WO0215662 and WO0217358 and in publications EP1219622, EP1184383, EP1184384, EP1184385, JP200203084. Statins contemplated to be
5 useful in the present inventions are atorvastatin calcium (Lipitor), cerivastatin sodium (Baycol), fluvastatin sodium (Lescol), lovastatin (Mevacor), pravastatin sodium (Pravachol), simvastatin (Zocor) and rosuvastatin (Crestor).

In another aspect the invention is a pharmaceutical composition comprising a combination of an $\alpha 7$ -nAChR agonist and a statin as described herein together with a
10 pharmaceutically-acceptable diluent or excipient.

In another aspect the present invention comprises providing neuroprotection or analgesia in a method of treatment or prophylaxis of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and
15 Parkinson's disease which method comprises administering a therapeutically effective amount of a combination as defined in Claim 1 to a patient.

In a particular aspect the method of the invention is a method for the treatment or prophylaxis of Alzheimer's disease.

A further aspect of the invention is the use of a combination of an $\alpha 7$ -nAChR agonist and a statin as described herein in the preparation of a medicament for providing
20 neuroprotection or analgesia in the treatment of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease.

In a particular aspect the use of a combination of an $\alpha 7$ -nAChR agonist and a statin as described herein is in the preparation of a medicament for the treatment or prophylaxis of
25 Alzheimer's disease.

A particular combination for use in the present invention comprises rosuvastatin or a pharmaceutically-acceptable salt thereof and an $\alpha 7$ -nAChR agonist selected from spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one, *N*-(1-azabicyclo[2.2.2]oct-3-yl)[*E*-3-(2-thienyl)propenamide], or (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine] or a pharmaceutically-acceptable salt thereof.
30

A particular pharmaceutical composition for use in the present invention comprises rosvastatin or a pharmaceutically-acceptable salt thereof and an $\alpha 7$ -nAChR agonist selected from spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one, *N*-(1-azabicyclo[2.2.2]oct-3-yl)[*E*-3-(2-thienyl)propenamide], or (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine] or a pharmaceutically-acceptable salt thereof together with a pharmaceutically acceptable diluent or carrier.

A particular method of the present invention is the provision of neuroprotection or analgesia for the treatment or prophylaxis of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease which method comprises administering a therapeutically effective amount of a combination of rosvastatin or a pharmaceutically-acceptable salt thereof and an $\alpha 7$ -nAChR agonist selected from spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one, *N*-(1-azabicyclo[2.2.2]oct-3-yl)[*E*-3-(2-thienyl)propenamide], or (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine] or a pharmaceutically-acceptable salt thereof to a patient. In particular the method is useful for the treatment or prophylaxis Alzheimer's disease.

A particular embodiment of the invention is the use of a combination rosvastatin or a pharmaceutically-acceptable salt thereof and an $\alpha 7$ -nAChR agonist selected from spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one, *N*-(1-azabicyclo[2.2.2]oct-3-yl)[*E*-3-(2-thienyl)propenamide], or (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine] or a pharmaceutically-acceptable salt thereof in the preparation of a medicament providing neuroprotection or analgesia for the treatment of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease. In particular the invention comprises the use of such a combination in the preparation of a medicament for the treatment of Alzheimer's disease.

Statins are compounds that inhibit HMG-CoA reductase, a rate-limiting enzyme in the biosynthetic pathway to cholesterol. Statins are conventionally used to reduce plasma levels of cholesterol in patients with cardiovascular disease but can also reduce A β serum levels in patients. Alpha-7-nAChR agonists beneficially activate $\alpha 7$ -nACh receptors and are useful for treating cognitive deficits and in the treatment of a range of disorders involving reduced cholinergic function such as Alzheimer's disease, cognitive or attention disorders, anxiety,

depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's disease. Accordingly, the hypothetical basis of the present invention lies in the realization that statins, by reducing the formation of A β , may be particularly effective in combination with α 7-nAChR agonists, which ameliorate cognitive deficits and inhibit neurodegeneration induced by A β , in the treatment of Alzheimer's disease. Therefore, the treatment of Alzheimer's disease with a combination of a statin and an α 7-nAChR agonist will result in enhanced efficacy over either type of agent if administered alone.

Experimental:

10 Assessment of the efficacy of a statin and an α 7-nAChR agonist in combination in animal models is not straightforward. Existing experimental models of Alzheimer's disease include transgenic mice, which over express A β , and animals with surgically generated fimbria-fornix lesions. These models and the uses to which they may be put are known, understood and appreciated by those of skill in the relevant art. Transgenic mice which over
15 express A β exhibit some of the clinical manifestations of Alzheimer's disease, *e.g.*, plaque deposition and, in some cases, cognitive deficits, but neurodegeneration is not observed. Animals with fimbria-fornix lesions have cognitive and learning deficits and have been used to assess potential approaches to treat neurodegeneration. No single experimental model exhibits the entire pathophysiological complex of Alzheimer's disease. However, to the
20 extent that these models do mimic the pathophysiology of Alzheimer's disease they may be used to assess the effect of a statin and an α 7-nAChR agonist in combination.

Claims:

1. A combination comprising:

- a statin selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin
5 sodium, simvastatin or rosuvastatin, or a pharmaceutically-acceptable salt thereof and
an $\alpha 7$ -nAChR agonist selected from spiro[1-azabicyclo[2.2.2]octane-3,5'-
oxazolidine]-2'-one,
(+)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one,
(-)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one,
10 spiro[1-azabicyclo[2.2.1]heptan-3,5'-oxazolidin-2'-one],
3'-methyl spiro-[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one],
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-phenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
15 5'-nitrospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
1'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline],
5'-(phenylcarboxamido)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
b]pyridine],
5'-(phenylaminocarbonylamino)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
20 b]pyridine],
5'-(phenylsulfonylamido)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
b]pyridine],
5'-aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-N-methylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
25 5'-N,N-dimethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-
b]pyridine],
5'-N,N-diethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-N-ethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-N-benzylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
30 5'-N-formamidospino[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
5'-N-acetamidospino[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline],
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]quinoline],

- 5'-ethenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(E)-(phenylethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(4-morpholino)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(1-azetidiny)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(E)-(2-(4-pyridyl)ethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(E)-(2-(2-pyridyl)ethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(2-trimethylsilylethynyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-ethynylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(2-furyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-(3-pyridyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-methylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5' carbonitrile],
 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5' carboxamide],
 5'-N'-(3-chlorophenyl)aminocarbonylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 5'-N'-(2-nitrophenyl)aminocarbonylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 4'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 4'-methoxyspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 4'-phenylthiospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 4'-(N-2-aminoethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 4'-phenylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 4'-methylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 4'-(4-N-methylpiperazin-1-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine],
 4'-chloro-spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[3,2-c]pyridine],
 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[3,2-c]pyridine],
 spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-7'-oxide],

- spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine-6'-carbonitrile],
6'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine],
6'-fluorospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine],
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylfuran-2-carboxamide),
5 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-thienyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-phenylbenzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-pyridyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),
10 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methoxyphenyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-methoxyphenyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-(*N*-acetylamino)phenyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-fluorophenyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methylphenyl)benzamide),
15 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-thienyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3,5-dichlorophenyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-naphthyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(3-(4-fluorophenyl)benzamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)furan-2-carboxamide),
20 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-thienyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-benzo[b]furanyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-thienyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)furan-2-carboxamide),
25 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-methoxyphenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-fluorophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-naphthyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methylphenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-furyl)furan-2-carboxamide),
30 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-furyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide),

- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(2-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(4-pyridyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-(3-pyridyl)thiophene-2-carboxamide),
5 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-nitrophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-trifluoromethylphenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)furan-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)thiophene-2-
10 carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-ethoxyphenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)furan-2-carboxamide),
15 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)thiophene-2-
carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-chlorophenyl)furan-2-carboxamide),
20 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiazole-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiazole-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)thiophene-2-
carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(8-quinoliny)thiophene-2-carboxamide),
25 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-3-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(4-phenylthiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-cyanophenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-methylamino)phenyl)thiophene-2-
carboxamide),
30 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-hydroxyphenyl)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridylamino)thiophene-2-carboxamide),
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)thiophene-2-carboxamide),

- N*-(1-aza-bicyclo[2.2.2]oct-3-yl)(5-(3-(4-morpholinyl)phenyl)thiophene-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(aminomethyl)phenyl)thiophene-2-carboxamide),
- 5 *N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenoxythiophene-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)furan-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)furan-2-carboxamide),
- N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-formylphenyl)thiophene-2-carboxamide); *N*-
- 10 (1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(hydroxymethyl)phenyl)thiophene-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylfuran-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-thienyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-phenylbenzamide),
- 15 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-pyridyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methoxyphenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-methoxyphenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-(*N*-acetylamino)phenyl)benzamide);
- 20 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-fluorophenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3-methylphenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-thienyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(3,5-dichlorophenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(2-naphthyl)benzamide),
- 25 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(3-(4-fluorophenyl)benzamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-thienyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-benzo[b]furanyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)furan-2-carboxamide),
- 30 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-thienyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-methoxyphenyl)furan-2-carboxamide),
- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-fluorophenyl)furan-2-carboxamide),

PRU-09-02

- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-naphthyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methylphenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-furyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-furyl)furan-2-carboxamide),
5 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(2-pyridyl)thiophene-2-carboxamide),
10 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(4-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-(3-pyridyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)furan-2-
carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-nitrophenyl)furan-2-carboxamide),
15 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-trifluoromethylphenyl)furan-2-
carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)furan-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-acetylamino)phenyl)thiophene-2-
carboxamide),
20 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-fluorophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-methoxyphenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-ethoxyphenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)furan-2-
carboxamide),
25 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3,5-dimethylisoxazol-4-yl)thiophene-2-
carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-3-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-chlorophenyl)furan-2-carboxamide),
30 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiazole-3-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiazole-3-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)thiophene-2-
carboxamide),

- (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(8-quinolinyl)thiophene-2-carboxamide),
(*S*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridyl)thiophene-2-carboxamide);
(*S*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(4-pyridyl)thiophene-2-carboxamide),
(*S*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide),
5 (*S*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenylthiophene-3-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(4-phenylthiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-cyanophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N*-methylamino)phenyl)thiophene-2-
10 carboxamide),
(*R*)-*N*-(1-aza-bicyclo[2.2.2]oct-3-yl)(5-(3-hydroxyphenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-pyridylamino)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-chlorophenyl)thiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(4-morpholinyl)phenyl)thiophene-2-
15 carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(aminomethyl)phenyl)thiophene-2-
carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-phenoxythiophene-2-carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-aminophenyl)furan-2-carboxamide) ,
20 (*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(*N,N*-dimethylamino)phenyl)furan-2-
carboxamide),
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-formylphenyl)thiophene-2-carboxamide), or
(*R*)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)(5-(3-(hydroxymethyl)phenyl)thiophene-2-
carboxamide), or a pharmaceutically-acceptable salt thereof.
- 25
2. A pharmaceutical composition comprising a combination according to Claim 1 together with a pharmaceutically acceptable diluent or carrier.
3. A method providing neuroprotection or analgesia for the treatment or prophylaxis of a
30 condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease which method comprises

administering a therapeutically effective amount of a combination as defined in Claim 1 to a patient.

4. The method according to Claim 3, for treatment or prophylaxis of Alzheimer's disease.
5. The use of a combination according to Claim 1 in the preparation of a medicament providing neuroprotection or analgesia for the treatment or prophylaxis of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease.
6. The use of a combination according to Claim 5, in the preparation of a medicament for the treatment or prophylaxis of Alzheimer's disease.
7. A combination according to Claim 1, wherein said statin is rosuvastatin or a pharmaceutically-acceptable salt thereof and said $\alpha 7$ -nAChR agonist is selected from:
spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one;
N-(1-Azabicyclo[2.2.2]oct-3-yl)[*E*-3-(2-thienyl)propenamide], or
(2'*R*)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'*H*)-furo[2,3-*b*]pyridine] or a pharmaceutically-acceptable salt thereof.
8. A pharmaceutical composition comprising a combination according to Claim 7 together with a pharmaceutically acceptable diluent or carrier.
9. A method providing neuroprotection or analgesia for treatment or prophylaxis of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease which method comprises administering a therapeutically effective amount of a combination as defined in Claim 7 to a patient.

10. The method according to Claim 9, for treatment or prophylaxis of Alzheimer's disease.
11. The use of a combination according to Claim 7, in the preparation of a medicament providing neuroprotection or analgesia for the treatment or prophylaxis of a condition or disorder involving reduced cholinergic function selected from Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, schizophrenia, Tourette's syndrome, and Parkinson's disease.
- 10 12. The use of a combination according to Claim 11, in the preparation of a medicament for the treatment or prophylaxis of Alzheimer's disease.

A B S T R A C T**Title: Alpha-7 Nicotinic Receptor Agonists and Statins In Combination**

- 5 Combinations of $\alpha 7$ -nAChR agonists and statins, pharmaceutical compositions containing the same and methods of using the same useful for treatment or prophylaxis of neurological degenerative diseases.

100822

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.